Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Negrier C ^a   Menart, C ^a   Attali, O ^a   Petit, P Y ^b   Lienhart, A ^a   Dechavanne, M ^a   Ingerslev, J ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

D dimers; F1+2; Factor IX; Factor VIII; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; BLOOD CLOTTING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINUOUS INFUSION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; THROMBOEMBOLISM; THROMBOSIS;

ADULT; BASAL METABOLISM; BLOOD COAGULATION; EVALUATION STUDIES; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM;

EID: 0031788184     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Lusher JM. Prediction and management of adverse events associated with the use of factor-IX complex concentrates. Semin Hematol 1977; 30:36-40.
2. Schimpf KL, Zeltsch CH, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A. Lancet 1982; ii:1043.
3. White GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic material and clues to the mechanism of thrombosis in vivo. Blood 1977; 49:159-170.
4. Hultin MB. Activated clotting factors in factor IX concentrates. Blood 1979; 54:1028-1038.
5. Phillippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, et al. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996; 76:23-28.
6. Giles AR, Nesheim ME, Hoogendoorn H, Tracey PB, Mann KG. The coagulant active phospholipid content is a major determinant of in vitro thrombogenicity of prothrombin complex (factor IX concentrates) in rabbits. Blood 1982; 59:401-407.
7. Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy of hemophilia A. Am J Hematol 1989; 32:85-88.
8. Bona RD, Weinstein RA, Weisman SJ, Bartolomeo A, Rickles FR. The use of continuous infusion of factor concentrates in the treatment of hemophilia A. Am J Hematol 1989; 32:8-13.
9. Hay CRM, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coag Fibrinol 1996; 7:15-19.
10. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with hemophilia. Br J Haematol 1992; 82:729-733.
11. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153-159.
12. Negrier C, Berruyer M, Durin A, Philippe N, Dechavanne M. Increased thrombin generation in a child with a combined factor IX and protein C deficiency. Blood 1993; 65:690-695.
13. Ville D, Clermont N, Trzeciak MC, Dechavanne M. Contribution of D-dimer levels in the diagnosis of deep vein thrombosis (DVT) after total hip replacement (THR) [abstract PS-176]. Thromb Haemost 1997; June (suppl):44.
14. McMillan CW, Webster WP, Roberts HR, Blythe WB. Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol 1970; 18:659-667.
15. Blatt PM, White CG II, MacMillan CW, Roberts HR. Treatment of factor VIII antibodies. Thromb Haemost 1977; 38:514-523.
16. Weinstein RE, Bona RD, Rickles FR. Continuous infusion of monoclonal antibody-purified factor VIII. Am J Hematol 1991; 36:211-212.
17. Martinowitz U, Schulman S. Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? Blood Coag Fibrinol 1996; 7:27-33.
18. Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65:28-32.
19. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79:606-611.